A new drug combo for EGFR-mutant lung cancer after osimertinib
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 trial tests the drug alisertib combined with osimertinib in people with advanced (stage IV) EGFR-mutant lung cancer. It looks at safety, dosing, and whether the combination can help control cancer that has not fully responded to osimertinib or has progressed on it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-small cell lung cancer confirmed by pathology (biopsy/surgery report).
- You are 18 or older, and you’re well enough to do daily activities (ECOG 0–1).
- Your tumor has a known EGFR mutation (or a blood test shows it) using a certified (CLIA) lab.
- Your cancer has measurable spots on scans, and you’ve had recent imaging showing progression (or in some groups, response) within the past 30 days.
- You must be currently taking osimertinib 80 mg daily and be able to swallow oral study drugs.
- You must meet recent blood/liver/kidney lab thresholds and be willing to provide fresh or stored biopsy tissue.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, osimertinib and etoposide, for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has stopped responding well to osimertinib alone. It may help if your cancer is stable or slowly getting worse on osimertinib as your first treatment.
This trial tests whether using a blood test (ctDNA) to guide targeted therapy after surgery can improve outcomes for patients with stage II-IIIA non-small cell lung cancer that has an EGFR mutation. If you qualify, you may receive a targeted pill (osimertinib) based on your ctDNA results.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This trial tests a combination of three targeted drugs (osimertinib, cetuximab, and tucatinib) for people with EGFR-mutant lung cancer that has gotten worse after osimertinib. The goal is to see if this new combination can shrink tumors or slow cancer growth.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
Hear when a new EGFR Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.